CD274 and non-small cell lung carcinoma: There are currently three PD‐1/PD‐L1 inhibitors approved by the FDA for NSCLC, namely nivolumab,7, 8 pembrolizumab,9 and atezolizumab.10 Intriguingly, the clinical application of PD‐1/PD‐L1 inhibitors has been met with controversy.